29053-27-8
29053-27-8 結(jié)構(gòu)式
基本信息
中文別名
美西拉宗 英文別名
W-2395NSC297623
Meseclazone
7-Chloro-3,3a-dihydro-2-methyl-2H,9H-isoxazolo[3,2-b][1,3]benzoxazin-9-one
3,3a-Dihydro-7-chloro-2-methyl-2H,9H-isoxazolo[3,2-b][1,3]benzoxazin-9-one
7-chloro-2-methyl-3,3a-dihydro-2H-[1,2]oxazolo[3,2-b][1,3]benzoxazin-9-one
2H,9H-Isoxazolo[3,2-b][1,3]benzoxazin-9-one, 7-chloro-3,3a-dihydro-2-methyl-
物理化學(xué)性質(zhì)
熔點(diǎn)148°C
沸點(diǎn)131.8°C (rough estimate)
密度1.3213 (rough estimate)
折射率1.5800 (estimate)
儲(chǔ)存條件-20°C儲(chǔ)存
溶解度溶于二甲基亞砜
酸度系數(shù)(pKa)-3.18±0.40(Predicted)
常見問題列表
生物活性
Meseclazone (W2395;NSC297623) 是一種非甾體抗炎藥 (NSAID)，具有抗炎，止痛和解熱活性。體內(nèi)研究
Meseclazone inhibits collagen-induced aggregation 1 and 4 hr after oral administration. Intravenous administration of Meseclazone and other nonsteroidal anti-inflammatory drugs caused a dose-dependent inhibition of bronchoconstriction resulting in the following order of descending potency: isoproterenol congruent to indomethacin greater than fenoprofen greater than tolmetin greater than aspirin greater than naproxen congruent to ibuprofen greater than phenylbutazone greater than diflunisal greater than Meseclazone greater than 5-CSA.